Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Researchers have provided evidence for distinct processes underlying vasodilator-responsive and nonresponsive idiopathic pulmonary arterial hypertension.
Systolic function is better preserved in patients with idiopathic pulmonary arterial hypertension if they have a higher right ventricle mass-to-volume ratio, research shows.
Patients with pulmonary arterial hypertension have peripheral muscle weakness that is independent of impairments in their respiratory muscles, research shows.
Structural features identifiable on computed tomography pulmonary angiography can provide prognostic information for patients with pulmonary arterial hypertension, say UK researchers.
Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it has initiated a Phase 1 single ascending dose study of TransCon Treprostinil in healthy volunteers.
Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.
A study of Chinese patients with systemic sclerosis has identified predictive markers for accompanying pulmonary arterial hypertension similar to those that have been identified in other ethnic groups.
Monitoring right ventricular parameters can give advance warning of clinical deterioration in stable patients with idiopathic pulmonary arterial hypertension, research suggests.
Measuring the duration of vortical blood flow in the main pulmonary artery allows accurate estimation of pulmonary blood pressure and diagnosis of pulmonary arterial hypertension, say researchers.
medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests.
Health-related quality of life before and during treatment for pulmonary arterial hypertension is significantly associated with survival, Brazilian researchers report.
Estimated right atrial pressure, measured using echocardiography, may be a useful prognostic indicator in patients with pulmonary arterial hypertension, a study suggests.
Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest.
Supraventricular arrhythmias are common and usually cause clinical deterioration in patients with idiopathic pulmonary arterial hypertension, a study shows.
Doppler echocardiography has good accuracy relative to right heart catheterisation for detecting pulmonary hypertension, shows a large study.
Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago.
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs.
Patients with pulmonary hypertension have reduced right ventricular strain and more dyssynchronous ventricles than healthy individuals, show results of a three-dimensional speckle tracking study.
Researchers from the Netherlands have identified three baseline variables that may qualify as treatment goals in children with pulmonary arterial hypertension.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.